Press Releases April 1, 2026 08:00 PM

Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026

Merit Medical Systems announces Q1 2026 earnings release and investor call scheduled for April 30, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
MMSI

Merit Medical Systems, a global healthcare technology company specializing in proprietary medical devices, will release its financial results for Q1 2026 after market close on April 30, 2026, followed by an investor conference call.

Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026
MMSI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Merit Medical Systems focuses on medical devices used in interventional, diagnostic, and therapeutic procedures across multiple specialties including cardiology, radiology, oncology, critical care, and endoscopy.
  • The company plans to release financial results and hold a conference call on April 30, 2026.
  • Merit employs approximately 7,600 individuals and serves customers globally through a robust sales and clinical support team.

SOUTH JORDAN, Utah, April 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2026, after the close of the stock market on Thursday, April 30, 2026. Merit plans to hold its investor conference call on the same day (Thursday, April 30, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).

To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.

A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.

Contacts:
   PR/Media Inquiries:
Sarah Comstock
Merit MedicalInvestor Inquiries:
Mike Piccinino, CFA, IRC
ICR Healthcare+1-801-432-2864+1-443-213-0509sarah.comstock@merit.commike.piccinino@icrhealthcare.com

Risks

  • Financial results may fall short of investor expectations impacting stock performance.
  • Market conditions in healthcare technology and medical device sectors could impact operational results.
  • Uncertainties related to global healthcare regulations and supply chain disruptions might affect company performance.

More from Press Releases

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer Sep 2, 2026 BioRestorative Therapies Announces Reverse Stock Split Sep 2, 2026 Capital Southwest Increases Corporate Credit Facility to $595 million and Extends Maturity to September 2031 Sep 2, 2026 Archimedes Tech SPAC Partners II Co. Announces Filing of Third Amendment to Registration Statement on Form S-4 with the SEC Sep 2, 2026 Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Third Quarter Common Stock Distribution of $0.1503 Per Share Sep 2, 2026